We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
ILLUCCIX gozetotide 25 micrograms kit for radiopharmaceutical preparation for use with Eckert & Ziegler GalliaPharm Ge 68/Ga-68 generator (UK)
Section 19A approved medicine
ILLUCCIX gozetotide 25 micrograms kit for radiopharmaceutical preparation for use with Eckert & Ziegler GalliaPharm Ge 68/Ga-68 generator (UK)
Section 19A approval holder
Telix Pharmaceuticals (ANZ) Pty Ltd ABN 20 620 871 730
Phone
03 9093 3880
Approved until
Status
Current
Medicines in short supply/unavailable
ILLUCCIX Configuration A Kit for the Preparation of Ga-68 Glu-urea-Lys(ahx)-hbed-CC 25 mcg solution for injection Glass Vial - ARTG 356332
Indication(s)
ILLUCCIX, after radiolabelling with Ga-68, is a radioactive diagnostic agent indicated for use with positron emission tomography (PET) imaging combined with Computerised Tomography (CT) in patients with prostate cancer:
- who are at risk of metastasis and who are suitable for initial definitive therapy.
- who have suspected recurrence based on elevated serum prostate specific antigen (PSA) level.
- for the selection of patients with metastatic prostate cancer in whom lutetium Lu 177 vipivotide tetraxetan PSMA-directed therapy is indicated.
Images
